We only found minimal genomic alterations of RASSF10 (2.4%) and ASPP2 (4.7%) compared to 62% of TP53 mutations in cancer cell lines (n = 881; Broad CCLE/Cancer Cell Line Encyclopedia; analyzed using [38]). The gene discussed is TP53; the disease is cancer.